Catecholamines may play an important role in the pathogenesis of transient mid- and basal ventricular ballooning

Eun-Mi Kim1, Jae-Hyeong Park, Yun Seon Park

  • 1Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.

Insights

Transient mid- and basal ventricular ballooning, a left ventricular (LV) variant, is not fully understood. Catecholamines may cause myocardial dysfunction, potentially explaining this syndrome.

Area of Science:

  • Cardiology
  • Cardiovascular Pathophysiology

Background:

  • Transient left ventricular (LV) ballooning syndromes are recognized cardiac conditions.
  • A novel variant, transient mid- and basal ventricular ballooning, has emerged.
  • The precise mechanisms driving this specific LV ballooning variant remain unclear.

Observation:

  • Two clinical cases of transient mid- and basal ventricular ballooning were documented.
  • Both cases exhibited a clear association with elevated catecholamine levels.
  • This association suggests a potential link between catecholamines and the observed cardiac phenomenon.

Findings:

  • Catecholamine excess is implicated as a potential trigger for transient mid- and basal ventricular ballooning.
  • Myocardial dysfunction induced by catecholamines is hypothesized as the underlying mechanism.
  • This finding offers a novel perspective on the pathogenesis of this LV ballooning variant.

Implications:

  • Understanding the role of catecholamines could lead to targeted therapeutic strategies.
  • Further research into catecholamine-mediated pathways is warranted for this specific syndrome.
  • This study contributes to the differential diagnosis and management of left ventricular dysfunction.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...